Ascelia Pharma AB (OSTO:ACE) 3-Year RORE % : -39.85% (As of Mar. 2026)


OSTO:ACE Ascelia Pharma AB OSTO:ACE
29 GF Score
Price kr0.81
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB 3-Year RORE %?

Ascelia Pharma AB OSTO:ACE -75.37% 29 3-Year RORE % is -39.85 as of Mar. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,289 Biotechnology companies, Ascelia Pharma AB ranks worse than 75.72% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Ascelia Pharma AB's 3-Year RORE % for the quarter that ended in Mar. 2026 was -39.85%.

The industry rank for Ascelia Pharma AB's 3-Year RORE % or its related term are showing as below:

OSTO:ACE's 3-Year RORE % is ranked worse than
75.72% of 1289 companies
in the Biotechnology industry
Industry Median: -11.53 vs OSTO:ACE: -39.85

Ascelia Pharma AB  (OSTO:ACE) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Ascelia Pharma AB 3-Year RORE % Related Terms


Ascelia Pharma AB 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB 3-Year RORE % Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only 8.07 -0.08 -2.15 -15.54 -37.91

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.97 -32.87 -41.98 -37.91 -39.85

OSTO:ACE vs VRTX, REGN, ALNY: 3-Year RORE % Comparison

For the Biotechnology subindustry, Ascelia Pharma AB's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascelia Pharma AB 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's 3-Year RORE % falls into.


OSTO:ACE
29GF Score
Ascelia Pharma AB OSTO:ACE
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB 3-Year RORE % Calculation

Ascelia Pharma AB's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.59--2.253 )/( -4.173-0 )
=1.663/-4.173
=-39.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -39.85 mean?
Ascelia Pharma AB (OSTO:ACE) has a 3-Year RORE % of -39.85 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Ascelia Pharma AB and its competitors. According to the industry distribution chart, Ascelia Pharma AB ranks #976 out of 1289 companies in the Biotechnology industry, placing it in the top 75.7%.
Is Ascelia Pharma AB's 3-Year RORE % too high?
Ascelia Pharma AB's current 3-Year RORE % is -39.85. Based on the distribution chart, Ascelia Pharma AB ranks #976 out of 1289 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascelia Pharma AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascelia Pharma AB ranks #976 out of 1289 companies for 3-Year RORE %. This places Ascelia Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current 3-Year RORE % is -39.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current 3-Year RORE % of -39.85. The current 3-Year RORE % is -39.85. Ascelia Pharma AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current 3-Year RORE % is -39.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
29GF Score

Get the complete analysis for OSTO:ACE

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.81
Price